The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
How do 4-year results from the BE SURE and BE BRIGHT trials of bimekizumab impact treatment selection for psoriatic disease?
Featured:
Paolo GisondiFollowing a recent rheumatology congress, the PsOPsA Hub was pleased to speak with Paolo Gisondi, University Hospital of Verona, Verona, IT. We asked, How do 4-year results from the BE SURE and BE BRIGHT trials of bimekizumab impact treatment selection for psoriatic disease?
4-year results from the BE SURE and BE BRIGHT trials of bimekizumab
Gisondi begins by discussing 4-year PASI response, why these data are clinically relevant, and how the long-term response compares to other treatments. Gisondi then speaks about the safety data from BE SURE and BE BRIGHT, and why safety is key in patients with psoriasis.
